Occam Places Adrian Schreyer as CTO of Anagenex
In March of 2024, Occam placed Adrian Schreyer as CTO at Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI) to discover the next generation of small molecule medicines.
Prior to joining Anagenex, he spent over a decade at Exscientia where he was a founding member of the team and went on to support the company through a successful IPO while building its AI team from scratch and eventually serving as the company’s Chief Technology Officer. The AI-enabled drug discovery engine he designed at Exscientia is one of the only AI platforms to drive compounds from discovery into the clinic. Adrian holds a B.Sc. in Applied Biology from the Bonn-Rhein-Sieg University of Applied Sciences and a Ph.D. in Structural Bioinformatics and Drug Discovery from the University of Cambridge.
Schreyer is the latest in a series of Occam placements at Anagenex including Ryan Kruger, CSO, Joe Franklin,SVP Early Discovery and Tito Serafini, Board Member.
Related Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.